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Abstract To provide guidelines on the correct applica-
tion of the acetate recovery factor in metabolic research,
we investigated the influence of exercise intensity and
infusion protocol on [1,2-13C]acetate label recovery
during exercise. Eight cyclists were studied during
[1,2-13C]acetate infusion for 1 h at rest followed by three
30-min stages of cycling exercise at a workload of 40, 55
and 75% maximal workload (Wmax), respectively (pro-
tocol 1). Four cyclists were subsequently studied fol-
lowing [1,2-13C]acetate infusion in three separate trials
while cycling at the same workloads but in the absence
of any pre-exercise infusion period (protocol 2). Finally,
we observed the cyclists during [1,2-13C]acetate infusion
at a 40% Wmax workload after 4 h of pre-exercise
infusion (protocol 3). Acetate recovery increased from
13.7 (0.4)%, after 1 h of rest, to a plateau value of 75.1
(2), 91.2 (0.7) and 101 (2)% during exercise at 40, 55 and
75% Wmax workloads, respectively. In protocol 2,
without prior infusion time, fractional label recovery
was substantially lower at each separate workload. In
contrast, when applying an extensive pre-exercise infu-
sion period of 4 h, acetate recovery rates were substan-
tially increased compared to the values observed in
protocols 1 and 2 during exercise at a 40% Wmax
workload. In conclusion, in contrast to resting condi-
tions, acetate recovery reaches a plateau value during
exercise. Though this plateau value is repeatedly used to
correct for label recovery in various exercise studies, our
data clearly show that acetate label recovery during ex-
ercise not only depends on the exercise intensity but also
on the applied infusion protocol. Therefore, theoretical
acetate recovery factors taken from previous literature
are not generally applicable.
Keywords Exercise Æ Metabolism Æ Stable
isotopes Æ Substrate utilization Æ Tracers
Introduction
In metabolic research, oxidation rates of substrates such
as fatty acids, carbohydrate and amino acids are tradi-
tionally measured by quantifying the amount of labelled
CO2 produced following the administration of
13C or
14C-labelled substrates. The main assumption when
using isotope tracer methodology is that the rate of
appearance of labelled CO2 in the expired breath
accurately reflects the oxidation rate of the applied
tracer. However, there is a need to correct for the pro-
portion of labelled CO2 that is produced via oxidation
but not excreted in the expired breath. A substantial
proportion of labelled CO2 has been shown to become
entrapped within the bicarbonate pool(s) of the body
(Irving et al. 1983; Leijssen and Elia 1996). In addition,
another substantial amount of label can be (temporarily)
lost via isotopic exchange reactions in the tricarboxylic
acid (TCA) cycle, mainly by way of conversion of
a-ketoglutarate to glutamate and glutamine (Pouteau et
al. 1998; Schrauwen et al. 1998). Sidossis et al. (1995a)
were the first to propose that label retention can be
quantitated by determining 13CO2 (
14CO2) production
during infusion of [13C]acetate (or [14C]acetate). Acetate,
converted to acetyl-CoA, immediately enters the TCA
cycle. Therefore, the fraction of acetate label retained in
the body should equal the fraction of substrate label
entrapped at any step between entering the TCA cycle
and its appearance in expired CO2. As such, an acetate
correction factor is applied to correct simultaneously for
the amount of label trapped as CO2 in the bicarbonate
pool(s), as well as for label fixated in other metabolites,
via those isotopic exchange reactions (Sidossis et al.
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1995a; van Hall 1999). Omitting to apply an acetate
recovery factor leads to a substantial underestimation of
plasma-derived fatty acid or glucose oxidation rates,
especially during resting conditions.
We have validated the [1,2-13C]acetate recovery fac-
tor for correction of [U-13C]palmitate oxidation mea-
sured at rest (Schrauwen et al. 1998). As the position of
the [13C] (or [14C]) label in the applied tracer influences
the amount of label retention (Baurle et al. 1998; Metges
et al. 1994; Trimmer et al. 2001; Wolfe and Jahoor
1990), an [1-13C]acetate tracer should be used to correct
oxidation rates of a [1-13C]glucose or fatty acid tracer,
while [1,2-13C]acetate should be used in the case of a
[1,2-13C] or [U-13C] tracer. As such, acetyl-CoA entering
the TCA cycle will have 13C atoms at the same position
in both the acetate as well as substrate tracer infusion
trial. At rest, we observed an intra-subject coefficient of
variance (CV) in acetate label recovery of 4.0 (1.5)%,
implying good reproducibility. However, inter-subject
CV was 8.3 (0.6)%, suggesting that an acetate correction
factor should be applied in each individual in parallel to
the substrate infusion trial (Schrauwen et al. 1998, 2000).
At rest, whole-body acetate recovery increases with
the duration of infusion (Mittendorfer et al. 1998; van
Hall 1999). Mittendorfer et al. (1998) observed a con-
tinuous increase in acetate recovery up to 11 h after the
onset of infusion. This implies that, during resting con-
ditions, fractional acetate label recovery depends on
infusion time and should be determined within the same
period used to calculate substrate tracer oxidation rates.
In contrast, during exercise acetate recovery has been
shown to plateau, with its plateau value determined by
exercise intensity (van Hall 1999). Subsequently, previ-
ously published acetate recovery factors are frequently
used to correct substrate tracer oxidation rates in exer-
cise studies. However, we hypothesize that pre-exercise
infusion time also plays a major role in determining the
absolute value of the obtained plateau in acetate re-
covery during exercise. We investigated the impact of
both exercise intensity and infusion protocol on acetate
label recovery during exercise. We, therefore, designed a
number of different protocols which were applied in part
to the same subjects to obtain additional data on intra-
individual variance in acetate label recovery during ex-
ercise. The obtained data are used to provide sound
advice on the proper use of the acetate recovery factor to
accurately correct tracer oxidation rates for label
retention in ongoing metabolic and clinical research.
Methods
Subjects
Eight trained cyclists [age: 22.1 (0.7) years; height: 1.86 (0.03) m;
body mass: 74.5 (2.2) kg; Wmax: 413 (9) W; _V O2max: 5.5 (0.2)
lÆmin)1)] were selected to perform in protocol 1. Four of the sub-
jects [age: 22.5 (0.5) years; height: 1.83 (0.02) m; body mass: 74.8
(2.7) kg; Wmax: 427 (10) W; _V O2max: 5.4 (0.2) lÆmin
)1] volunteered
to perform three additional trials in protocol 2 and another
additional trial in protocol 3. Subjects were informed about the
nature and risks of the experimental procedures before their written
informed consent was obtained. This study was approved by the
local Medical Ethical Committee.
Pre-testing
Maximum workload (Wmax) was measured on an electronically
braked cycle ergometer (Lode, Groningen, The Netherlands) dur-
ing an incremental exhaustive exercise test 1 week before the first
experimental trial (Kuipers et al. 1985). Findings were used to
determine the 40, 55 and 75% Wmax workload applied in protocols
1–3. Maximum oxygen uptake ( _V O2max) was measured to express
the relative exercise intensity as % _V O2max.
Diet and activity prior to testing
All subjects consumed a high carbohydrate meal [85 kJÆkg body
mass)1; consisting of 69 energy % (En%) carbohydrate, 15 En%
fat and 16 En% protein] the evening before each trial. All subjects
were instructed not to consume any products with a high natural
abundance of 13C (carbohydrate derived from C4 plants: corn,
sugar cane) 1 week before and during the entire experimental pe-
riod to minimize any shifts in background enrichment. They were
also instructed to refrain from any exercise training 2–3 days prior
to each trial.
Experimental trials
Protocol 1 was performed to study the effects of incremental
exercise on acetate recovery. Therefore, subjects performed an
incremental exercise protocol including three different workloads.
In protocol 2, we determined the acetate recovery factor during
exercise at each of those workloads separately, in the absence of
any pre-exercise infusion period. Finally, in protocol 3 we further
investigated the impact of the applied infusion protocol by deter-
mining the acetate recovery factor during the 40% Wmax workload
following an extended 4-h pre-exercise infusion period.
Protocol 1
The subjects arrived at the laboratory at 8.00 a.m. after an over-
night fast. A Teflon catheter (Baxter BV, Utrecht, The Nether-
lands) was inserted in an antecubital vein for isotope infusion.
After placement of the catheter subjects rested on a reclining chair
and, approximately 20 min later, oxygen consumption and carbon
dioxide production measurements were started and vacutainer
tubes (Becton Dickinson, France) were filled directly from the
mixing chamber in duplicate to determine background 13C/12C
ratio in expired CO2. Immediately thereafter, subjects were ad-
ministered a single intravenous dose of 0.064 mgÆkg)1 of NaH13-
CO3 to prime the bicarbonate pool. At t=0 a constant intravenous
infusion of [1,2-13C]acetate (0.0736 lmolÆmin)1Ækg)1) was started
and continued for 150 min. After 60 min acetate infusion rates
were doubled (0.1472 lmolÆmin)1Ækg)1) and subjects started to
exercise on a cycle ergometer at an intensity of 40% Wmax for a 30-
min period. At t=90 exercise intensity was increased up to 55%
Wmax for another 30-min period. This was followed by a final 30-
min period at 75% Wmax. At rest _V O2 and _V CO2 were measured
continuously during the first 60 min (Oxycon-b, Mijnhardt, Bun-
nik, The Netherlands). During exercise _V O2 and _V CO2 were
measured every 5 min before breath sampling. Breath samples were
collected at t=0, 50, 55, 60 min (rest); 80, 85, 90 min (40% Wmax);




Four of the cyclists participating in protocol 2 reported after an
overnight fast at the laboratory on three additional occasions.
Subjects were administered a single intravenous dose of
0.064 mgÆkg)1 NaH13CO3. Immediately thereafter, exercise and the
infusion of [1,2-13C]acetate (at the same infusion rate as applied in
protocol 1: 0.1472 lmolÆmin)1Ækg)1) were started (t=0 min) and
continued for up to 60 min. Exercise was performed on a cycle
ergometer at an intensity of 40, 55 or 75% Wmax. _V O2 and _V CO2
were measured every 5 min before breath sampling. Breath samples
were collected at t=0, 10, 20, 30, 40, 50 and 60 min. All trials were
randomized and separated by at least 7 days.
Protocol 3
Cyclists that participated in protocol 2 reported after an overnight
fast at the laboratory for an additional trial. After catheter inser-
tion and background measurements (see protocol 1) subjects were
administered a single intravenous dose of 0.064 mgÆkg)1 NaH13-
CO3 to prime the bicarbonate pool. At t=0 a constant intravenous
infusion of [1,2-13C]acetate (at the same resting infusion rate as
applied in protocol 1: 0.0736 lmolÆmin)1Ækg)1) was started and
continued for 240 min. After 240 min acetate infusion rates were
doubled (at the same exercise infusion rates as applied in protocols
1–2: 0.1472 lmolÆmin)1Ækg)1) and subjects started to exercise on a
cycle ergometer at an intensity of 40% Wmax for a 60-min period.
Thereafter, acetate infusion was continued for an additional 60 min
into the post-exercise period. _V O2 and _V CO2 were measured every
5 min before breath sampling. Breath samples were collected at
t=0, 60, 120, 180, 210, 220, 230, 235, 240, 245, 250, 260, 270, 285,
300, 305, 310, 315, 330 and 360 min.
Analysis
The acetate tracer (sodium salt of [1,2-13C]acetate, 98.9% enriched;
Cambridge Isotope Laboratories, Andover, Mass., USA) was dis-
solved in 0.9% saline. The chemical and isotopic purity (98.9%) of
the acetate tracer was checked by 1H and 13C NMR and GC/MS.
In each infusate the exact acetate concentration was measured us-
ing an enzymatic method (Boehringer, Mannheim, Germany).
Breath samples were analysed for 13C/12C ratio by gas chroma-
tography isotope ratio mass spectrometry (GCIRMS) (Finnigan
MAT 252, Bremen, Germany).
Calculations




in which sa indicates sample and bk indicates background value.
Fractional recovery of label in breath CO2, derived from the in-
fusion of labelled acetate, was calculated as follows:
Fractional recovery of label ð%Þ ¼ ½ðTTR CO2  _V CO2Þ=2F   100%
ð2Þ
where TTR CO2 is tracer/tracee ratio (TTR) in breath CO2, _V CO2
is carbon dioxide production (mmolÆmin)1) and F is the infusion
rate of [1,2-13C]acetate (mmolÆmin)1).
Statistics
All data are expressed as mean (SE). Statistical analysis of the data
collected was done using a two-factor analysis of variance (ANO-
VA). Differences in acetate label recovery during exercise of various
intensities was checked for statistical significance using a Scheffé
post hoc test. In addition, simple regression analysis was performed
to calculate correlation between the oxygen uptake/pre-exercise
infusion duration and fractional acetate label recovery and between
acetate recovery factors obtained in protocols 1–3. Statistical sig-




12CO2 ratios are shown in Fig. 1A. Ratios
increased over time under resting conditions (0–60 min).
During exercise, ratios remained constant over the last
10–15 min of each exercise stage. Label recovery aver-
aged 13.7 (0.4)% at the end of the resting period. Ace-
tate recovery was significantly higher during exercise and
averaged 75.1 (1.6), 91.2 (0.7) and 101.1 (1.9)% at the
end of the 40, 55 and 75% Wmax workload, respectively.
Fractional acetate recovery was significantly different
between the various exercise intensities (Fig. 1B). _V O2
averaged 2.41 (0.07), 3.11 (0.08) and 3.91 (0.11) lÆmin)1
[44.1 (1), 56.8 (0.8) and 71.6 (1.6)% _V O2max] during the
last 15 min of the 40, 55 and 75% Wmax exercise stage,
respectively. Simple regression showed a significant
correlation between _V O2 and acetate recovery (R=0.80;
P<0.0001). Inter-subject CV for acetate label recovery
Fig. 1A, B Breath 13CO2/
12CO2
ratios over time (A) and
calculated fractional acetate
recovery (B) at rest and during
incremental exercise at an
exercise intensity of 40, 55 and





difference compared to resting
conditions; #significant
difference compared to 40%
Wmax;
^significant difference
compared to 55% Wmax
(P<0.05)
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12CO2 ratios over time during exercise at
an intensity of 40, 55 and 75% Wmax are illustrated in
Fig. 2A. Breath 13CO2/
12CO2 ratios increased over time
and in the absence of a pre-exercise infusion period did
not reach a plateau value within 30–60 min. In the 75%
Wmax trial subjects exercised until exhaustion which
turned out to be less than 40 min in three subjects.
Subsequently, ratios are only reported up to 30 min at
the 75% Wmax workload. Over the last 30 min fractional
acetate recovery averaged 66.9 (3.2) and 71.2 (1.3)% in
the 40 and 55% Wmax trial, respectively (Fig. 2B). In the
75% Wmax trial fractional acetate recovery increased up
to an average of 74.9 (6.0)% after 30 min. Differences in
fractional acetate recovery rates between the different
exercise intensities within this protocol did not reach
statistical significance, but fractional acetate recovery
rates at each workload (in the absence of pre-exercise
label infusion) were substantially lower than recovery
rates observed following 1 h of pre-exercise infusion
(protocol 1; P<0.05). Inter-subject CV for acetate label
recovery during exercise averaged 9.8%.
Protocol 3
Breath TTR ratios over time at rest and during exercise
at an intensity of 40% Wmax are illustrated in Fig. 3A.
Ratios increased gradually at rest over the entire 4-h
period. At the onset of exercise, ratios decreased and
gradually reached plateau values after 60 min of exer-
cise. After exercise, ratios started to increase over time
during post-exercise recovery. Fractional acetate label
recovery (Fig. 3B) increased up to 36.9 (2.0)% at rest,
after 4 h of infusion. After onset of exercise, label re-
covery increased up to 142.2 (2.2)% and gradually
reached a plateau at 97.6 (6.0)% during the last 10 min
of exercise. In the post-exercise stage, acetate label re-
covery dropped to 10.5 (1.1)% within 5 min, after which
label recovery gradually increased. Inter-subject CV for
acetate label recovery at rest and during exercise was
11.7% and 10.5%, respectively.
Protocols 1–3
Fractional acetate recovery rates during exercise fol-
lowing 0, 1 or 4 h of pre-exercise [1,2-13C]acetate infu-
sion are shown in Fig. 4. Fractional acetate label
recovery following continuous [1,2-13C]acetate infusion
during moderate intensity exercise (at 40% Wmax) in the
absence of, after 1 h and after 4 h of pre-exercise label
Fig. 2A, B Breath 13CO2/
12CO2 ratios over time (A) and calculated
fractional acetate recovery (B) during exercise at different intensi-
ties (40, 55 and 75% Wmax) following continuous intravenous
[1,2-13C]acetate infusion, started immediately at the onset of
exercise without any pre-exercise infusion period. *Significantly
lower value compared to fractional acetate recovery rates observed
with pre-exercise infusion period (protocol 1) (P<0.05)
Fig. 3A, B Breath 13CO2/
12CO2
ratios over time (A) and
calculated fractional acetate
recovery (B) at rest, during
moderate intensity exercise
(40% Wmax) and in the post-
exercise resting phase following
continuous intravenous
[1,2-13C]acetate infusion,
started 4 h before the onset of
exercise
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infusion averaged 66.9 (3.2), 75.1 (1.6) and 97.6 (6)%,
respectively (P<0.05). Regression analysis showed a
significant positive correlation between the pre-exercise
acetate label infusion period and the fractional acetate
label recovery during the subsequent exercise stage
(P<0.001). When the individual acetate recovery factors
obtained at the 40% Wmax workload in protocol 1 were
compared in a scatter plot to the values obtained in
protocols 2 and 3, strong correlations were found;
R=0.98 and 0.96 (P<0.05), respectively. Inter-
individual CV in acetate recovery during exercise in
protocols 1–3, averaged 9.0 (1.6)%.
Discussion
When carbon-labelled glucose or fatty acid tracers are
used to determine substrate oxidation rates, corrections
should be made for labelled CO2 that is produced but
not excreted as well as for label fixated in other metab-
olites (Schrauwen et al. 1998; Sidossis et al. 1995a; van
Hall 1999). An acetate correction factor has been de-
signed to provide a practical means to correct for such
label retention (Sidossis et al. 1995a; Tounian et al.
1996). Omitting to apply an acetate correction factor
leads to substantial underestimation of plasma-derived
glucose or fatty acid oxidation rates (Mittendorfer et al.
1998; Schrauwen et al. 1998, 2000; Sidossis et al. 1995a).
When implementing the use of [14C]acetate, both acetate
and the 13C substrate tracer can be applied within one
single trial, but in many places medical ethical consid-
erations limit the use of radioactive tracers. As such,
when using stable isotope methodology to determine
substrate tracer oxidations rates, a separate acetate
recovery trial needs to be performed in parallel with the
tracer infusion trial to correct for carbon label retention.
We studied the effects of both exercise and infusion
protocol on 13C label recovery following continuous
[1,2-13C]acetate infusion.
First, we measured acetate recovery rates during in-
cremental exercise to determine the effects of exercise
intensity on label recovery within a single trial. At rest,
acetate recovery increased continuously. In contrast,
during exercise acetate recovery reached a plateau value
after 15 min during each exercise stage (Fig. 1A). The
plateau values in fractional acetate recovery rates were
significantly different between the three exercise stages
(Fig. 1B). During exercise at the 75% Wmax workload,
acetate recovery actually reached a plateau at 100%,
implying no need for a correction factor for label re-
tention. In line with findings on label recovery following
[1-14C]acetate infusion (Sidossis et al. 1995a), we ob-
served a strong correlation between [1,2-13C]acetate la-
bel recovery and _V O2 (R=0.8; P<0.0001). Sidossis et al.
(1995a) reported label recovery to range between 66 and
94%, as exercise intensity varied between 23 and 81%
peak _V O2 in 11 random subjects.
The increase in acetate recovery with increasing _V O2
is explained by the fact that there is less chance for label
to be fixated via TCA cycle exchange reactions at a
higher workload. This is a consequence of the fact that
TCA-cycle flux increases in proportion to exercise in-
tensity, while exchange reactions (e.g. glutamine pro-
duction in muscle) maintain a constant pace. In the
study by Sidossis et al. (1995a), 100% label recovery was
not obtained, though exercise intensities as high as 81%
of peak _V O2 were applied. The latter can be explained
by the inclusion of trained cyclists in the present study,
who are able to cycle at much higher absolute workloads
and concomitant _V O2 rates [3.9 (0.1) lÆmin
)1], enabling
us to demonstrate that full 100% label recovery can be
achieved.
Our findings, in accordance with others (van Hall
1999), show that, in contrast to resting conditions, ace-
tate label recovery tends to plateau during exercise with
its plateau value being determined by the applied exer-
cise intensity (Schrauwen et al. 2000; Sidossis et al.
1995a). Subsequently, published acetate recovery factors
are currently used to correct fatty acid tracer oxidation
rates in exercise studies. Whether this is a valid approach
has never been thoroughly investigated. Schrauwen et al.
(2000) recently reported an inter-subject CV in acetate
label recovery of 12% at rest and 16% during a subse-
quent exercise trial. In the present study, in a more
homogenous group of cyclists, inter-subject CV was
12% and 8%, respectively (protocol 1). In comparisons
between studies, differences in reported acetate recovery
rates during exercise are often much larger than the re-
ported inter-subject CV of 8–16%, which cannot entirely
be explained by differences in exercise intensity, body
composition of the subjects and/or specific tracers used.
We hypothesized that acetate label recovery during
exercise not only depends on exercise intensity but also
Fig. 4 Fractional acetate recovery rates during moderate intensity
exercise (40% Wmax) following continuous intravenous [1,2-
13C]ac-
etate infusion, started immediately at the onset of exercise,
following 1 h and following 4 h of pre-exercise infusion. *Signif-
icantly higher compared to protocol 1 (0 h); #significantly higher
compared to protocol 2 (1 h) (P<0.05)
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on the applied infusion protocol. As we have shown that
a substantial proportion of label is lost by way of con-
version of a-ketoglutarate to glutamate and glutamine
(Schrauwen et al. 1998; Sidossis et al. 1995a, 1995b), it
could be hypothesized that differences in infusion pro-
tocol could lead to the accumulation of label in the
glutamate/glutamine pools. As such, preceding infusion
time determines the extent to which the glutamine and
glutamate pools will become labelled and subsequently
oxidized. Previous research (Gibala et al. 1997; Sahlin
et al. 1995; van Hall et al. 1995) has shown that the
muscle glutamate pool is reduced during exercise in
proportion to exercise intensity, as this pool is used for
the generation of TCA cycle intermediates. This implies
that more 13CO2 will be generated during exercise when
the muscle glutamate pool becomes more enriched fol-
lowing a longer pre-exercise infusion period. As such,
with increasing (pre-exercise) infusion time, the extent of
label recovery during exercise and the subsequent pla-
teau value in fractional label recovery could be affected.
To test this hypothesis, we determined acetate label
recovery during exercise at 40, 55 and 75% Wmax
workload in separate trials with the omission of any pre-
exercise infusion time (protocol 2). In agreement with
the hypothesis, lower acetate recovery rates were ob-
tained using protocol 2 compared to protocol 1 at each
separate workload (Figs. 1, 2). Clearly, the reduced re-
covery rates as well as the less pronounced differences in
label recovery between the different exercise intensities
are well in accordance with our hypothesis. In the ab-
sence of any pre-exercise acetate infusion, less label is
incorporated into the glutamate pool. Subsequently,
during exercise less 13CO2 is generated following re-
duction of the glutamate pool. In addition, as the
glutamate pool is reduced in proportion to exercise in-
tensity, absolute differences in acetate label recovery
during exercise of various intensities will depend on the
extent of 13C enrichment of the glutamate pool.
To further validate our hypothesis we extended the
pre-exercise infusion period to 4 h followed by exercise
at the 40% Wmax workload (under identical infusion
conditions as used in protocols 1–2). Following the onset
of exercise, acetate recovery increased up to 142 (2)%,
after which it declined, reaching a plateau value of
100% (Fig. 3). These data provide further proof of the
proposed relationship between pre-exercise infusion time
and acetate label recovery during exercise. As the glu-
tamine/glutamate pool becomes substantially enriched
with 13C label during the extensive 4-h resting period,
more 13CO2 is recovered with the onset of exercise when
the glutamate pool declines. As such, acetate recovery
temporarily increases above 100% as the excessive
amount of entrapped label is released. Within 60 min a
new equilibrium is attained showing full ~100% label
recovery. The impact of the infusion protocol on frac-
tional acetate label recovery during exercise is illustrated
in Fig. 4, and reveals a strong positive correlation be-
tween pre-exercise infusion time and the obtained pla-
teau value in label recovery (P<0.001). Regression
analyses, comparing acetate label recovery rates
observed in protocol 1 with those seen in protocol 2 and 3,
approached 1.00 (R=0.98 and 0.96, respectively;
P<0.05). This indicates that there are individual factors
which determine whether subjects have a high or low
acetate label recovery in repeated exercise tests per-
formed under different experimental conditions. The
overall inter-subject CV on label recovery during ex-
ercise averaged 9.0 (1.6)% in the present study, con-
firming and extending our previous conclusions
(Schrauwen et al. 1998, 2000) that there is a need for a
separate acetate recovery trial within each individual
subject even when (pre-)infusion conditions do not vary.
In summary, to accurately correct 13C tracer oxida-
tion rates for carbon label retention, an acetate recovery
factor needs to be applied. Omitting to apply an acetate
correction factor leads to a gross underestimation of
tracer oxidation rates at rest and, in most cases, a sub-
stantial underestimation during exercise. In contrast to
resting conditions, acetate label recovery reaches an
apparent plateau value during exercise. Though values
obtained from previously published studies are repeat-
edly used to correct for label retention in studies per-
formed in other laboratories and/or under different
conditions, our data clearly show that acetate label re-
covery during exercise depends on the applied exercise
intensity, pre-exercise infusion time as well as on the
individual subjects used in the studies. As such, theo-
retical acetate recovery factors should not be generally
used. Our advice is that an acetate correction test should
be determined in every subject, for the same period (at
rest) and preceded by the same pre-exercise infusion
protocol and workload (during exercise conditions) as
applied in the substrate tracer infusion trial.
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